Patents

Patents are legal documents drawn up by inventors and lawyers and granted by various patent offices around the world, to protect the inventors' intellectual property. The short description accompanying each patent in this Patents section is therefore taken from the legal document as is, with minor corrections for Greek symbols and obvious spelling errors. The patents included in this section may be for material products (defensins or defensin-like peptides or nucleic acid sequences, synthetic or natural) or for novel methods of detecting, quantitating, synthesizing, or delivering antimicrobial peptides/nucleic acid sequences in general. The curators' criterion for inclusion in this section is broader for novel methods than for material products, in the hope that these methods may in future be similarly applied to defensins.

Patents in which the defensins or defensin-like material products and methods as above are not novel, such as biomarker sets containing unmodified defensin or defensin-like peptides or oligonucleotides, are excluded from this section. The exception to such exclusions is where the patent provides other novel defensin-related material products or methods in addition to those non-novel of the biomarker set itself. This exclusion is because the reasonable presence of defensin or defensin-like sequences or indeed any other sequences in patented biomarker sets is necessarily attributed to some prior discovery of disease state correlation with such sequences. The curators have observed therefore that the novel discovery in biomarker-related patents is often the method of biomarker array analysis and validation as well as its resultant implications for diagnostics and prognostics. The expert evaluation of such biomarker analysis and validation is well outside the scope of the Defensins Knowledgebase. The reader is respectfully referred to a biomarker database specific to the disease to perform his own assessment of the validity of the biomarker.

Methods not pertaining to the antimicrobial activity of defensins, but where defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences are suggested in some unambiguous detail to play a useful role in the method, with or without supporting experimental evidence, are included as well in this section. Patents in which natural defensins are up/downregulated in a clearly defined signal transduction pathway as a result of the unrelated patented novel compound or method are also included. And lastly, all patents showing experimental work done with defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences, where such peptides or nucleic acid sequences are not the experimental controls, are included without exception.

The data in this section have been extracted from the academic version of SciFinder Scholar 2007 and from public Google search - a wide range of defensin-related patents are included.

Keywords:

Results 151 - 160 of 333

<< Previous | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | Next >>

Last updated: 20th February 2008

Patents
Patent No.: WO 045976
Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis.
Applicant: Lim DJ, Lee H-Y, Webster P, Andalibi A, Li J-D, Ganz T (2003)
Disclosed herein is a compound and a method for the treatment of otitis media and paranasal sinusitis using human defensins, lysozyme and/or lactoferrin as a new class of non-antibiotic antimicrobials. From studies of otitis media and paranasal sinusitis, it was observed that certain innate immune modulators were important in the body's response to the infection. Therefore, these innate immune modulators, lysozyme, lactoferrin, and defensins were tested for use as a non-antibiotic treatment for infection, particularly infections such as otitis media and sinusitis.

Patent No.: WO 044049
Plectasin, a defensin from the ebony cup fungus Pseudoplectania nigrella.
Applicant: Schnorr KM, Hansen MT, Mygind PH, Segura DR, Kristensen H-H (2003)
The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.

Patent No.: WO 040297
Protein and cDNA sequences of oil palm EGAD1, a new protein of defensin family.
Applicant: Cheah SC, Tregear JW (2003)
The invention relates to new protein of the defensin family, its isolated polypeptide and an isolated polynucleotide encoding it. The invention further relates to the uses of the polynucleotide and or polypeptide, including its use to detect the mantled abnormality of oil palm.

Patent No.: WO 024992
Protein sequences of human and mouse antimicrobial peptides beta-defensins and its therapeutic use.
Applicant: McCray PB Jr., Schutte BC, Jia HP, Casavant TL, Welsh MJ (2003)
The present invention employs an iterative application of BLAST and Hidden Markov Model based searches which identified 34 multi-drug genes in the human genome and 48 in the mouse genome. The invention relates to antimicrobial agents and to methods of preventing microbial growth. In particular, the present invention involves compns. comprising an antimicrobial peptide and method for its use. The present invention relates to novel antimicrobial peptides and derivs. thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amt. of the peptide alone or in combination with other antimicrobial agents antibiotics.

Patent No.: WO 007989
Anti-microbial targeting chimeric pharmaceuticals.
Applicant: Shi W, Morrison SL, Trinh K, Wims L, Chen L, Anderson MH, Qi F (2003)
The present invention is based on the discovery of a compn. that provides a targeted anti-microbial effect. Specifically the compn. contains a targeting moiety which recognizes a target microbial organism and an anti-microbial peptide moiety which has anti-microbial activity. In addn., the present invention provides methods of treating a microbial infection, e.g., on mucosal surfaces by using the compns. provided by the present invention.

Patent No.: WO 000863
Defensin polynucleotides from plants and methods of their use as pesticides and for modulating development and defense responses.
Applicant: Cahoon RE, Herrmann R, Harvell LT, Lu AL, Mccutchen BF, Navarro APA, Simmons CR, Wong JFH (2003)
Methods and compounds for modulating development and defense responses are provided. Particularly, isolated nucleic acids having nucleotide and encoded amino acid sequences for defensins from plants are provided. The nucleotide sequences of the invention encode small cysteine-rich proteins and are variously annotated or described as defensins, defensin-like proteins, antimicrobial peptides, anti-pathogenic peptides, thionins, antifungal peptides, protease inhibitors, amylase inhibitors, scorpion toxin-like proteins, and small cysteine-rich proteins. They are referred to as defensins as they exhibit similarity in primary structure to insect defensins. The sequences can be used in expression cassettes for modulating development, developmental pathways, and defense responses. Transformed plants, plant cells, tissues, and seed are also provided.

Patent No.: US 6642203
Crustacean antimicrobial peptides.
Applicant: Destoumieux D, Bachere E, Bulet P (2003)
The invention concerns antimicrobial peptides obtained from penaeid prawns having the following characteristics: a molecular mass of about 5 to 7 kDa; a pHi not less than 9; an N-terminal portion comprising a region (A) of about 15 to 25 amino acids rich in proline; and a C-terminal portion comprising a region (B) of about 20 to 30 amino acids and containing 6 cysteine residues forming three intramolecular disulfide bonds. The invention also concerns the nucleic acid sequences coding for said peptides and enabling their production by genetic engineering.

Patent No.: US 6635740
Ligand/lytic peptide compositions and methods of use.
Applicant: Enright FM, Jaynes JM, Hansel W, Koonce KL, McCann SM, Yu WH, Melrose PA, Foil LD, Elzer PH (2003)
Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to specifically inhibit cells that are driven by or are dependent upon a specific ligand interaction; for example, to induce sterility or long-term contraception, or to attack tumor cells, or to selectively lyse virally-infected cells, or to attack lymphocytes responsible for autoimmune diseases. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in animals in vivo. Administering in vivo a combination of a ligand and a membrane-active lytic peptide kills cells with a receptor for the ligand. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes.) Lysis of tumor cells is rapid. The two components--the ligand and the lytic peptide--may optionally be administered as a fusion peptide, or they may be administered separately, with the ligand administered slightly before the lytic peptide, to activate cells with receptors for the ligand, and thereby make those cells susceptible to lysis by the lytic peptide. The compounds may be used in gene therapy to treat malignant or non-malignant tumors, and other diseases caused by clones or populations of "normal" host cells bearing specific receptors (such as lymphocytes), because genes encoding a lytic peptide or encoding a lytic peptide/peptide hormone fusion may readily be inserted into hematopoietic stem cells or myeloid precursor cells. The lytic peptide tested was hecate, a synthetic peptide analog of melittin.

Patent No.: US 6630351
Compositions and methods for drug delivery using pH sensitive molecules.
Applicant: Monahan SD, Wolff JA, Hagstrom JE, Budker VG, Rozema DB (2003)
A system relating to the delivery of desired compounds (e.g., drugs and nucleic acids) into cells using pH-sensitive delivery systems. The system provides compositions and methods for the delivery and release of a compound to a cell.

Patent No.: US 6630197
Inhibition of sulfate-reducing-bacteria-mediated degradation using bacteria which secrete antimicrobials.
Applicant: Wood TK, Jayaraman A, Earthman JC (2003)
The present invention relates to the field of degradation or corrosion prevention or inhibition through the use of bacteria which secrete antimicrobial chemical compositions. In particular, the invention relates to the use of bacteria which, either naturally or through the use of recombinant technology, secrete chemical compositions which inhibit the growth of sulfate-reducing bacteria on metals, concrete, mortar, and other surfaces subject to corrosion.